A recent study indicated that the PLK1 inhibitor BI2536 has the potential to trigger pyroptosis in ESCC cells by enhancing the expression of GSDME in the cytoplasm and activating the caspase-3/GSDME pathway. Here, CASP3 is linked to esophageal squamous cell carcinoma.